The Contrast Agent Molecular Engineering Laboratory (CAMEL) is led by Marty Pagel, Ph.D., who has developed a multidisciplinary career in chemistry, biochemistry, biomedical engineering, radiology, and cancer research. CAMEL has developed molecular imaging methods that evaluate biomarkers of the tumor microenvironment. We have developed a MRI method that measures extra cellular pH, which can assess tumor acidosis that causes resistance to immunotherapy, and can evaluate metabolic changes in tumors caused by chemotherapy. More recently, we have combined PET and MRI to evaluate the combination of glucose uptake and lactic acid production caused by upregulated glycolysis in tumors. We have also developed and patented analysis methods that improve the evaluation of vascular perfusion using MRI and MSOT imaging methods, which can assess the potential of drug delivery to a solid tumor. We have developed MRI and MSOT methods that detect enzyme activities within tumors, which are responsible for driving metastasis and can be used to evaluate early response to anti-cancer treatment. Finally, we are implementing methods with MSOT that assess tumor hypoxia.
Published Articles in MIB:
Minhas, A.S., Sharkey, J., Randtke, E.A. et al. Measuring Kidney Perfusion, pH, and Renal Clearance Consecutively Using MRI and Multispectral Optoacoustic Tomography. Mol Imaging Biol 22, 494–503 (2020). https://doi.org/10.1007/s11307-019-01429-z
Corbin, B.A., Pollard, A.C., Allen, M.J. et al. Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging. Mol Imaging Biol 21, 193–199 (2019). https://doi.org/10.1007/s11307-019-01315-8
Pagel, M.D. Recommendations for Reviewers of Biomedical Imaging Grant Applications. Mol Imaging Biol 21, 612–619 (2019). https://doi.org/10.1007/s11307-018-1297-5
Goldenberg, J.M., Cárdenas-Rodríguez, J. & Pagel, M.D. Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [18F]FDG PET and acidoCEST MRI. Mol Imaging Biol 20, 575–583 (2018).